Nature Communications | Cancer Immunotherapy Targeting Myeloid Cells Depends on Endosomal Pattern Recognition

This study reveals the critical role of endosomal TLR signaling pathways in the efficacy of MARCO and PD-L1-targeted therapies, suggesting that the innate immune sensing status within the tumor microenvironment may determine responsiveness to immunotherapy, offering new insights for optimizing myeloid cell-targeting strategies.

 

Literature Overview

The article titled 'Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition,' published in Nature Communications, systematically investigates how antibody-based therapies targeting tumor-associated macrophages (TAMs) in mouse tumor models depend on endosomal pattern recognition receptors (such as TLR9) to activate anti-tumor immune responses. The study finds that although anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibodies can reprogram TAMs and enhance T-cell infiltration, this effect is entirely dependent on functional endosomal TLR signaling.

Background Knowledge

Please elaborate in detail: 1. The challenge of tumor immunotherapy resistance addressed by this study. 2. Current research bottlenecks in TAMs. 3. The study's entry point.**Extensive embedding of entity placeholders required here**. Currently, although immune checkpoint inhibitors such as anti-PD-1/PD-L1 have significantly improved outcomes for patients with various cancers, a large number of patients still exhibit primary or acquired resistance, the mechanisms of which are not fully understood. Tumor-associated macrophages (TAMs) are among the major immunosuppressive myeloid cells in the tumor microenvironment (TME), often overexpressing molecules such as MARCO and PD-L1, promoting immune escape and suppressing T-cell function. TAM-targeting strategies, such as blocking CSF-1R or CD47, have shown promise in preclinical models, but their efficacy is limited by TAM heterogeneity and plasticity. Moreover, effectively reprogramming immunosuppressive TAMs into pro-inflammatory phenotypes remains a major challenge. This study focuses on whether TAM responses to targeted therapy depend on their intrinsic innate immune sensing capabilities, particularly endosomal TLR family members—TLR3, TLR7, TLR9—which recognize nucleic acid ligands to activate downstream signaling and regulate inflammatory responses and antigen presentation. Previous studies have shown that TLR agonists can enhance anti-tumor immunity, but their role in antibody-mediated myeloid-targeted therapy remains unclear. Therefore, the authors hypothesize: Is endosomal TLR signaling a necessary condition for the efficacy of αMARCO and αPD-L1? This hypothesis provides a new dimension for understanding immunotherapy resistance—namely, that the host’s innate immune state may determine treatment success or failure.

 

 

Research Methods and Experiments

The authors employed two mouse tumor models—B16-F10 melanoma and EO771 breast cancer—combined with genetically engineered animal models and single-cell RNA sequencing (scRNA-seq) to systematically dissect the role of endosomal TLR signaling in immunotherapy. First, using Unc93b1^3d/3d mutant mice (lacking functional TLR3, TLR7, and TLR9), they found that αMARCO and αPD-L1 treatments completely failed in these mice, as evidenced by uncontrolled tumor growth, reduced infiltration of CD8+ T cells and NK cells, and decreased IFN-γ secretion. In contrast, αPD-1 therapy, which directly targets T cells, remained effective, indicating that the defect specifically affects myeloid-targeted therapies. Flow cytometry and immunohistochemical analyses revealed that although TAMs in Unc93b1^3d/3d mice expressed MARCO, they could not be reprogrammed into a pro-inflammatory phenotype by αMARCO, as indicated by failed upregulation of MHC II and impaired downregulation of CD206. Furthermore, scRNA-seq analysis of TAM heterogeneity revealed that αMARCO treatment drove H2-Ab1+ and Spp1+ TAM subsets in wild-type (WT) mice toward pro-inflammatory polarization—a process absent in Unc93b1^3d/3d mice. Additionally, CellChat analysis showed that communication between TAMs and T cells shifted from immunosuppressive to immunostimulatory, a transition dependent on endosomal TLR signaling.

Key Conclusions and Perspectives

• The anti-tumor effects of αMARCO and αPD-L1 are entirely dependent on endosomal TLR signaling, whereas αPD-1 therapy is not—indicating that the efficacy of myeloid-targeted therapies is regulated by the host’s innate immune status, which has important implications for designing combination therapies
• TLR9 is the key receptor enabling MARCO⁺ macrophages to respond to αMARCO therapy, as its deletion in Marco-Cre; Tlr9^flox/flox mice completely abolishes therapeutic efficacy—highlighting TLR9 as a potential biomarker and therapeutic target
• TLR9 enables TAMs to respond to αMARCO by regulating the transcription of NLRP3 inflammasome-related genes—revealing a molecular pathway of TLR9→inflammasome→TAM repolarization, providing a new direction for mechanistic studies
• Combining TLR9 agonists (e.g., CpG ODN) significantly enhances the efficacy of αMARCO—suggesting that TLR9 agonists are a rational combination strategy to improve response rates in myeloid-targeted immunotherapy

Research Significance and Prospects

This study fundamentally changes our understanding of the mechanisms underlying myeloid-targeted immunotherapy, emphasizing the decisive role of the host’s innate immune state in treatment response. The conventional view holds that antibody therapies primarily function via Fc receptor-mediated ADCP or T-cell reactivation. However, this study reveals that endosomal TLR signaling acts as a 'licensing signal' for TAM functional reprogramming, providing a new mechanism to explain clinical resistance. From a drug development perspective, this finding supports including TLR9 agonists in combination regimens to 'prime' TAMs and enhance their sensitivity to targeted antibodies. In clinical monitoring, assessing TLR9 activity or inflammasome gene signatures in patient tumors may help predict the efficacy of αMARCO-like drugs. Moreover, this mechanism may also apply to other antibody therapies that rely on endocytosis-endosome pathways, broadening our understanding of antibody functional diversity.

 

 

Conclusion

This study establishes endosomal pattern recognition—particularly TLR9 signaling—as a molecular 'switch' for myeloid-targeted cancer immunotherapy. At a time when resistance to cancer immunotherapy is becoming an increasing clinical bottleneck, this work reveals that not all TAMs can be easily reprogrammed; their responsiveness depends on the intrinsic innate immune state of the cells. This finding provides new biomarkers for patient stratification (e.g., TLR9 activity) and designs novel combination strategies to overcome resistance (e.g., αMARCO + TLR9 agonist). From bench to bedside, the elucidation of this mechanism advances the therapeutic paradigm from 'target blockade' to 'immune sensing state modulation.' For tumor types enriched with TAMs, such as breast cancer and melanoma, evaluating TLR9 pathway activity in the TME may become a crucial component of future precision immunotherapy. Meanwhile, this study reminds us that developing new myeloid cell-targeting drugs must take into account the heterogeneity of the host immune background to achieve truly personalized treatment. This discovery provides critical molecular evidence for building disease modeling systems that more accurately reflect clinical responses (e.g., humanized mice), potentially accelerating the translation of next-generation immunotherapies.

 

Yueyun Pan, Shengduo Pei, Heng Liang, Tracy L McGaha, and Mikael C I Karlsson. Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition. Nature Communications.